Piascledine (Avocado-Soybean Unsaponifiables) for Osteoarthritis
Piascledine may provide modest symptomatic benefit for knee osteoarthritis but should not be relied upon as a disease-modifying therapy, and the evidence does not support its use for hip osteoarthritis.
Evidence Quality and Recommendations
The most recent high-quality guideline evidence comes from the 2019 EULAR hand OA recommendations 1 and 2019 ACR/Arthritis Foundation guidelines 2, which notably do not recommend avocado-soybean unsaponifiables (ASU) for routine use. The 2019 EULAR hand OA guideline explicitly states: "Currently, however, there is no evidence for clinical efficacy of these preparations [including ASU]" and emphasizes "at this moment in OA no drugs are available with disease-modifying properties, and therefore these substances should also not be advocated as such" 1.
Symptomatic Efficacy
Knee Osteoarthritis
- Effect size is small: Meta-analysis shows pain reduction (effect size 0.39) and Lequesne index improvement (effect size 0.45) 3
- A 2019 systematic review found ASU significantly decreased VAS pain scores (weighted mean difference: -17.36 mm) and Lequesne index in knee OA specifically 4
- Number needed to treat is 6 (range 4-21), meaning 6 patients must be treated for one to benefit 3
Hip Osteoarthritis
- No symptomatic benefit demonstrated: The 2019 meta-analysis found ASU did not significantly improve pain or function in hip OA 4
- The 2005 EULAR hip OA guidelines noted one small trial (n=50) showed benefit, but this was contradicted by a larger trial (n=163) showing no effect 5
Disease-Modifying Claims
The evidence for structure modification is unconvincing and contradictory:
- The ERADIAS trial (2014) showed 20% fewer radiographic progressors with ASU versus placebo (40% vs 50%, p=0.040) but no difference in mean joint space narrowing (-0.638 mm vs -0.672 mm, p=0.72) 6
- A 2026 rabbit model study found no reduction in cartilage fibrillation, subchondral bone loss, or collagen remodeling with long-term ASU treatment 7
- Earlier EULAR guidelines (2000-2007) consistently stated that while SYSADOA including ASU "may possess structure modification properties," this required confirmation with standardized methodology 8, 9
Dosing and Duration
If you choose to trial ASU despite limited evidence:
- Dose: 300 mg once daily 10
- Trial duration: 3 months minimum to assess response 3
- Treatment duration: Studies used 3-12 months; one comparative trial used 6 months 3, 10
Safety Profile
ASU has excellent safety with minimal adverse events:
- Adverse events comparable to placebo (relative risk 1.02,95% CI 0.83-1.25) 4
- No serious safety concerns identified in clinical trials 6, 10
- Well-tolerated with once-daily dosing potentially improving compliance versus three-times-daily alternatives 10
Clinical Algorithm
For knee OA patients:
- Start with evidence-based first-line therapies: exercise, education, weight loss (if BMI ≥25), and paracetamol/acetaminophen 11
- Add topical or oral NSAIDs if inadequate response 11
- Consider ASU only if patient requests it or prefers to avoid NSAIDs, with clear counseling that:
- Effect size is small (pain reduction ~17 mm on 100 mm VAS)
- 5 out of 6 patients will not benefit beyond placebo
- No proven disease-modifying effect
- Trial for 3 months; discontinue if no benefit
For hip OA patients:
- Do not recommend ASU - no demonstrated efficacy 4
Critical Caveats
- Publication bias concern: Most positive trials were industry-sponsored 3
- Heterogeneity: Significant variability between studies (I² = 83.5% for pain outcomes) 3
- Cost-effectiveness not established: Older EULAR guidelines noted "pharmacoeconomic aspects are not well established" 5, 9
- Not a substitute for proven therapies: Should never replace exercise, weight management, or NSAIDs when indicated
Monitoring
No specific laboratory monitoring required given the excellent safety profile. Assess clinical response at 3 months using:
- Pain scores (VAS or numerical rating scale)
- Functional assessment (WOMAC or Lequesne index)
- Patient global assessment
Discontinue if no meaningful improvement after 3 months, as continued use is unlikely to provide benefit.